Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia

Leukemia

Volumn 19, Issue 10, 2005, Pages 1788-1793

  Motta, M ^a   Rassenti, L ^b   Shelvin, B J ^a   Lerner, S ^a   Kipps, T J ^b   Keating, M J ^a,b   Wierda, W G ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CLL Research Consortium   (United States)

Author keywords

CD152; Chronic lymphocytic leukemia; CLL; CTLA 4; T reg

Indexed keywords

CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD152; PROTEIN KINASE ZAP 70; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLONAL ANERGY; CONTROLLED STUDY; CYTOGENETICS; DRUG MECHANISM; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOSTIMULATION; LEUKEMIA CELL; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

EID: 27144559654     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403907     Document Type: Article

References (20)

1. Matutes E, Wechsler A, Gomez R, Cherchi M, Catovsky D. Unusual T-cell phenotype in advanced B-chronic lymphocytyc leukemia. Br J Haematol 1981; 49: 635-642.
2. Pavkovic M, Georgievski B, Cevreska L, Spiroski M, Efremov DG. CTLA-4 exon 1 polymorphism in patients with autoimmune blood disorders. Am J Hematol 2003; 72: 147-149.
3. Cinek T, Sandra A, Imboden JB. Cutting edge: Tyrosine-independent transmission of inhibitory signals by CTLA-4. J Immunol 2000; 164: 5-8.
4. Kuiper HM, Brouwer M, Linsley PS, Van Lier RAW. Activated T cells can induce high levels of CTLA-4 expression on B cells. J Immunol 1995; 155: 1776-1783.
5. Magistrelli G, Jeannin P, Herbault N, Benoit de Coignac A, Gauchat JF, Bonnefoy JY et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999; 29: 3596-3602.
6. Rossi E, Matutes E, Morilla R, Owusu-Ankomah K, Heffernan AM, Catovsky D. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 1996; 10: 494-497.
7. Van den Hove LE, Van Gool SW, Vandeberghe P, Bakkus M, Thielemans K, Boogaerts MA et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by upregulation of CD80 and CD86 costimulatory molecules. Leukemia 1997; 11: 572-580.
8. Scrivener S, Kaminski ER, Demaine A, Prentice AG. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: Evidence of immune dysregulation. Br J Haematol 2001; 112: 959-964.
9. Frydecka I, Kosmaczewska A, Bocko D, Ciszak L, Wolowiec D, Kuliczkowski K et al. Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukemia. Br J Cancer 2004; 90: 2042-2048.
10. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295-302.
11. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192: 303-310.
12. high regulatory cells in human peripheral blood. J Immunol 2001; 167 1245-1253.
13. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893-901.
14. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993; 177: 925-935.
15. Van den Hove LE, Vandenberghe P, Van Gool SW, Ceuppens JL, Demuynck H, Verhoef GE et al. Peripheral blood lymphocyte subsets in patient with untreated hematological tumors: Evidence for systemic activation of the T cell compartment. Leuk Res 1998; 22: 175-184.
16. +T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285-1294.
17. Pioli C, Gatta L, Ubaldi V, Doria G. Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor. J Immunol 2000; 165: 5530-5536.
18. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985-988.
19. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173: 1444-1453.
20. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168 4272-4276.